glp-1 drugs microdosing vs. Standard Dosing: A Provider-Guided Comparison Why GLP-1 Microdosing? A Closer
Description
Investigators, Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono), Diabetes care, 35 (2012) 12251231
IIH patients treated with GLP-1Ras also required lower doses of acetazolamide compared to controls (10)
Peripheral artery disease and risk of cardiovascular events in patients with coronary artery disease: insights from the Heart and Soul Study
The FDA compounding enforcement actions have made accessing tirzepatide more complicated for some patients
Coverage depends on your insurance company, pharmacy benefits, diagnosis, BMI, medical necessity, and prior authorization requirements
